SpineX eyes FDA submission as neurogenic bladder trial hits milestone

SpineX has closed recruitment for a clinical study investigating its neuromodulation device to treat urinary incontinence.

Data from the trial, which began in May 2022, will be used to support a De Novo submission to the US Food and Drug Administration (FDA) “in the coming months”, according to SpineX’s CEO Parag Gad.